LPL Financial LLC Purchases 18,000 Shares of Humacyte, Inc. (NASDAQ:HUMA)

LPL Financial LLC raised its position in Humacyte, Inc. (NASDAQ:HUMA) by 3.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 529,992 shares of the company’s stock after purchasing an additional 18,000 shares during the period. LPL Financial LLC owned approximately 0.42% of Humacyte worth $2,676,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Vontobel Holding Ltd. bought a new stake in shares of Humacyte in the 4th quarter valued at $50,000. Brookstone Capital Management acquired a new position in Humacyte in the fourth quarter valued at about $56,000. ACT Wealth Management LLC acquired a new position in Humacyte in the fourth quarter valued at about $57,000. HighTower Advisors LLC bought a new stake in shares of Humacyte in the fourth quarter worth about $66,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Humacyte during the fourth quarter worth about $99,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HUMA has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Humacyte in a research note on Wednesday, March 12th. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Wednesday, March 26th. Finally, Benchmark restated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Down 2.5 %

Shares of HUMA opened at $1.53 on Friday. Humacyte, Inc. has a twelve month low of $1.15 and a twelve month high of $9.97. The stock has a market capitalization of $221.61 million, a P/E ratio of -1.14 and a beta of 1.62. The company has a 50 day moving average of $2.87 and a 200-day moving average of $4.17.

Humacyte (NASDAQ:HUMA) last released its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The business had revenue of $7.23 million during the quarter, compared to the consensus estimate of $0.64 million. On average, sell-side analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Insider Activity at Humacyte

In related news, Director Kathleen Sebelius acquired 50,000 shares of the business’s stock in a transaction dated Tuesday, April 8th. The stock was bought at an average price of $1.32 per share, with a total value of $66,000.00. Following the acquisition, the director now owns 91,207 shares in the company, valued at $120,393.24. This represents a 121.34 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.20% of the stock is owned by company insiders.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.